Paul Horstmeier - Feb 7, 2022 Form 4 Insider Report for Health Catalyst, Inc. (HCAT)

Role: Chief Operating Officer
Signature: /s/ Daniel Orenstein, as Attorney-in-Fact
Stock symbol: HCAT
Transactions as of: Feb 7, 2022
Transactions value $: -$179,041
Form type: 4
Date filed: 2/9/2022, 05:07 PM
Previous filing: Jan 6, 2022
Next filing: Feb 28, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	HCAT	Common Stock	Options Exercise	$66K	+4.17K	+4.31%	$15.84	101K	Feb 7, 2022	Direct
transaction	HCAT	Common Stock	Options Exercise	$67.8K	+6.58K	+6.53%	$10.30	107K	Feb 7, 2022	Direct
transaction	HCAT	Common Stock	Sale	-$211K	-7.27K	-6.77%	$28.97	100K	Feb 7, 2022	Direct	F1, F2
transaction	HCAT	Common Stock	Sale	-$102K	-3.48K	-3.47%	$29.38	96.7K	Feb 7, 2022	Direct	F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	HCAT	Stock Option (Right to Buy)	Options Exercise	$0	-4.17K	-8.7%	$0.00	43.7K	Feb 7, 2022	Common Stock	4.17K	$15.84	Direct	F4
transaction	HCAT	Stock Option (Right to Buy)	Options Exercise	$0	-6.58K	-23.42%	$0.00	21.5K	Feb 7, 2022	Common Stock	6.58K	$10.30	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 15, 2020, in accordance with Rule 10b5-1.
F2	Represents the weighted average sale price of the shares sold ranging from $28.24 to $29.23 per share, inclusive.
F3	Represents the weighted average sale price of the shares sold ranging from $29.25 to $29.57 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnotes (2) and (3).
F4	25% of the 186,467 shares underlying the option vested in an annual installment and the remaining balance vested or will vest in equal monthly installments until the option vests in full on February 5, 2023.
F5	25% of the 28,111 shares underlying the option vested in an annual installment and the remaining balance vested in equal monthly installments until the option vested in full on October 28, 2019.